



**SDI Review Form 1.6**

|                          |                                                                                             |
|--------------------------|---------------------------------------------------------------------------------------------|
| Journal Name:            | <a href="#">International Journal of TROPICAL DISEASE &amp; Health</a>                      |
| Manuscript Number:       | Ms_IJTDH_43041                                                                              |
| Title of the Manuscript: | Clinical Interpretation and Diagnostic Relevance of Hepatitis B Serological Profile Testing |
| Type of the Article      | Review Paper                                                                                |

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

**PART 1: Review Comments**

|                                     | Reviewer's comment                                                                                                                                                                                                                                                                                                                                                               | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)                                                                                                                                   |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Compulsory</b> REVISION comments | <p><b>Line 66: What is the role of HBeAg in addition to HBsAg and IgM Anti-HBc in acute infection?</b></p> <p><b>Line 73: What is the role of IgG anti-HBc and IgG Anti-HBs in chronic hepatitis B infection?</b></p> <p><b>Line 181-182: During window period or after the window period? IgG Anti-HBc may be the only antibody found during hepatitis B window period.</b></p> | Detail information on these serological markers in question are highlighted in the subtitle "Serological markers of hepatitis b virus infections" (Line 168-215)                                                                                                                                                |
| <b>Minor</b> REVISION comments      | <p>Line 44: Remove comma, let the sentence flow</p> <p>Line 91: HBV and genome should be spaced</p> <p>Line 127: OBI is of clinical or clinic relevance?</p>                                                                                                                                                                                                                     | "OBI is of clinic relevance and a public health concern due to the risk of reactivation it poses to individuals with previous history of HBV infection along with patients co-infected with hepatitis C virus/human immunodeficiency virus and patients undergoing chemotherapy". This was lifted from line 127 |
| <b>Optional/General</b> comments    | Since the topic is on serology, methinks lines 66-71, 74-79, 81-115 can be abridged serologically                                                                                                                                                                                                                                                                                | This might not be necessary considering the fact that this review aims at providing myriad of relevant information to guide healthcare providers in the diagnosis, treatment and management of those infected with Hepatitis B virus (HBV).                                                                     |